Cargando…

Drug Interactions in Lenacapavir-Based Long-Acting Antiviral Combinations

Long-acting (LA) anti-HIV regimens show promise for increasing dosing intervals and consequently, improving the patients’ quality of life. The first FDA-approved LA therapy is Cabenuva, which comprises rilpivirine (a non-nucleoside reverse transcriptase inhibitor) and cabotegravir (integrase strand...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cilento, Maria E., Ong, Yee Tsuey, Tedbury, Philip R., Sarafianos, Stefan G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9229705/ https://www.ncbi.nlm.nih.gov/pubmed/35746673 http://dx.doi.org/10.3390/v14061202

Ejemplares similares

Lenacapavir: First Approval
por: Paik, Julia
Publicado: (2022)

Long-acting lenacapavir acts as an effective preexposure prophylaxis in a rectal SHIV challenge macaque model
por: Bekerman, Elena, et al.
Publicado: (2023)

Long-acting lenacapavir protects macaques against intravenous challenge with simian-tropic HIV
por: Swanstrom, Adrienne E., et al.
Publicado: (2023)

Correction to: Lenacapavir: First Approval
por: Paik, Julia
Publicado: (2023)

73. Interim Resistance Analysis of Long-Acting Lenacapavir in Treatment-Naïve People with HIV at 28 Weeks
por: VanderVeen, Laurie, et al.
Publicado: (2021)

1581. Weight and Metabolic Changes with Long-Acting Lenacapavir in a Combination Regimen in Treatment-Naïve People with HIV-1 at Week 80
por: Kumar, Princy N, et al.
Publicado: (2023)

Mechanisms of Action of the Host-Targeting Agent Cyclosporin A and Direct-Acting Antiviral Agents against Hepatitis C Virus
por: Liu, Dandan, et al.
Publicado: (2023)

1585. Efficacy and safety of long-acting subcutaneous lenacapavir in heavily treatment-experienced people with multi-drug resistant HIV: Week 52 results
por: Ogbuagu, Onyema, et al.
Publicado: (2022)

1596. Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People with Multi-Drug Resistant HIV: Week 104 Results
por: Ogbuagu, Onyema, et al.
Publicado: (2023)

Rotten to the core: antivirals targeting the HIV-1 capsid core
por: McFadden, William M., et al.
Publicado: (2021)

1542. Impact of Subcutaneous Administration Sites on the Clinical Pharmacokinetics of Lenacapavir, a Long-Acting HIV Capsid Inhibitor: Does Body Site Matter?
por: Lat, Allen K, et al.
Publicado: (2023)

Long-Acting Anti-HIV Drugs Targeting HIV-1 Reverse Transcriptase and Integrase
por: Singh, Kamal, et al.
Publicado: (2019)

Visualization of Positive and Negative Sense Viral RNA for Probing the Mechanism of Direct-Acting Antivirals against Hepatitis C Virus
por: Liu, Dandan, et al.
Publicado: (2019)

Antiviral drugs specific for coronaviruses in preclinical development
por: Adedeji, Adeyemi O, et al.
Publicado: (2014)

Structural and Mechanistic Bases of Viral Resistance to HIV-1 Capsid Inhibitor Lenacapavir
por: Bester, Stephanie M., et al.
Publicado: (2022)

Lenacapavir with Fostemsavir in a Multidrug-Resistant HIV-Infected Hemodialysis Patient
por: Bigirimana, Ferdinand, et al.
Publicado: (2023)

GS-CA1 and lenacapavir stabilize the HIV-1 core and modulate the core interaction with cellular factors
por: Selyutina, Anastasia, et al.
Publicado: (2021)

Drug Interactions with the Direct-Acting Antiviral Combination of Ombitasvir and Paritaprevir-Ritonavir
por: Badri, Prajakta S., et al.
Publicado: (2015)

HIV/HCV Antiviral Drug Interactions in the Era of Direct-acting Antivirals
por: Rice, Donald P., et al.
Publicado: (2016)

Drug-drug interactions with direct-acting antivirals — less is more
por: Wong, Grace Lai-Hung
Publicado: (2021)

Comparison of anti-SARS-CoV-2 activity and intracellular metabolism of remdesivir and its parent nucleoside
por: Tao, Sijia, et al.
Publicado: (2021)

Drug–Drug Interactions Between Direct-Acting Antivirals and Psychoactive Medications
por: Smolders, E. J., et al.
Publicado: (2016)

HIV-1 Resistance to Islatravir/Tenofovir Combination Therapy in Wild-Type or NRTI-Resistant Strains of Diverse HIV-1 Subtypes
por: Cilento, Maria E., et al.
Publicado: (2023)

Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model
por: Beck, Bo Ram, et al.
Publicado: (2020)

Visualization of HIV-1 RNA Transcription from Integrated HIV-1 DNA in Reactivated Latently Infected Cells
por: Ukah, Obiaara B., et al.
Publicado: (2018)

HIV Capsid Protein Genetic Diversity Across HIV-1 Variants and Impact on New Capsid-Inhibitor Lenacapavir
por: Troyano-Hernáez, Paloma, et al.
Publicado: (2022)

Discovery of New Small Molecule Hits as Hepatitis B Virus Capsid Assembly Modulators: Structure and Pharmacophore-Based Approaches
por: Senaweera, Sameera, et al.
Publicado: (2021)

Highlights on the Development, Related Patents, and Prospects of Lenacapavir: The First-in-Class HIV-1 Capsid Inhibitor for the Treatment of Multi-Drug-Resistant HIV-1 Infection
por: Dzinamarira, Tafadzwa, et al.
Publicado: (2023)

Fr134 SARS-COV-2 INDUCES EPITHYELIAL-NEURONAL CROSSTALK STIMULATING VASOACTIVE INTESTINAL PEPTIDE RELEASE AS A POTENTIAL MECHANISM OF COVID-19-ASSOCIATED DIARRHEA
por: He, Peijian, et al.
Publicado: (2021)

Drug-drug interactions between direct-acting antivirals and statins in the treatment of chronic hepatitis C
por: Kuo, Meng-Hsuan, et al.
Publicado: (2020)

Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis
por: Hsu, Po-Yao, et al.
Publicado: (2021)

Drug–Drug Interactions of Newly Approved Direct-Acting Antiviral Agents in Patients with Hepatitis C
por: Gao, Lu-Hua, et al.
Publicado: (2021)

Small-Molecule RAF265 as an Antiviral Therapy Acts against PEDV Infection
por: Wang, Jing, et al.
Publicado: (2022)

Long-acting antiviral agents for HIV treatment
por: Margolis, David A., et al.
Publicado: (2015)

Sa1273: ENTERIC NEURONAL VASOACTIVE INTESTINAL PEPTIDE MEDIATES SARS-COV-2 ASSOCIATED DIARRHEA
por: Balasubramaniam, Arun, et al.
Publicado: (2022)

Bioequivalent pharmacokinetics for generic and originator hepatitis C direct-acting antivirals
por: Hill, Andrew, et al.
Publicado: (2018)

Incidence of depression in patients with hepatitis C treated with direct-acting antivirals
por: Egmond, Elfi, et al.
Publicado: (2019)

The MEK1/2 Inhibitor ATR-002 (Zapnometinib) Synergistically Potentiates the Antiviral Effect of Direct-Acting Anti-SARS-CoV-2 Drugs
por: Schreiber, André, et al.
Publicado: (2022)

Broad-Spectrum Antivirals and Antiviral Drug Combinations
por: Oksenych, Valentyn, et al.
Publicado: (2022)

Pharmacokinetics and Drug–Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine
por: Hodge, Daryl, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gvi7hnujd4663hctncivdaomt4